S100A4 and neoplasm: Bevacizumab treatment enhances tumor infiltration by neutrophils and increases S‐protein expression in neutrophils, contributing to neutrophil infiltration into tumors and increasing S100A4 expression in glioma cells, interfering with the efficacy of bevacizumab to promote tumor progression [212].